Low dose intravenous cangrelor versus glycoprotein IIb/IIIa inhibitors in endovascular treatment of tandem lesions
Jumaa M, Rodriguez-Calienes A, Dawod G, Vivanco-Suarez J, Hassan A, Divani A, Oliver M, Ribo M, Petersen N, Abraham M, Fifi J, Guerrero W, Malik A, Siegler J, Nguyen T, Sheth S, Yoo A, Linares G, Janjua N, Quispe-Orozco D, Galecio-Castillo M, Zevallos C, Malaga M, Farooqui M, Jovin T, Zaidi S, Ortega-Gutierrez S. Low dose intravenous cangrelor versus glycoprotein IIb/IIIa inhibitors in endovascular treatment of tandem lesions. Journal Of Stroke And Cerebrovascular Diseases 2023, 32: 107438. PMID: 37883826, PMCID: PMC11271813, DOI: 10.1016/j.jstrokecerebrovasdis.2023.107438.Peer-Reviewed Original ResearchMeSH KeywordsCohort StudiesGlycoproteinsHumansIntracranial HemorrhagesPlatelet Aggregation InhibitorsRetrospective StudiesTreatment OutcomeConceptsSymptomatic intracranial hemorrhageGP IIb/IIIa inhibitorsRate of symptomatic intracranial hemorrhageGP IIb/IIIaAntiplatelet therapyMechanical thrombectomyRetrospective non-randomized cohort studyGP IIb/IIIa inhibitor groupHemorrhagic infarction type 1Tandem lesionsComplete reperfusionType 1Periprocedural antiplatelet therapyReducing hemorrhage ratesParenchymal hematoma type 1Treatment of tandem lesionsNon-randomized cohort studyAcute carotid stentingIntravenous (IVGlycoprotein IIb/IIIa inhibitorsRate of complete reperfusionAssociated with increased oddsCangrelor groupHemorrhage rateIntravenous cangrelorSafety Outcomes of Mechanical Thrombectomy Versus Combined Thrombectomy and Intravenous Thrombolysis in Tandem Lesions
Rodriguez-Calienes A, Galecio-Castillo M, Farooqui M, Hassan A, Jumaa M, Divani A, Ribo M, Abraham M, Petersen N, Fifi J, Guerrero W, Malik A, Siegler J, Nguyen T, Yoo A, Linares G, Janjua N, Quispe-Orozco D, Tekle W, Alhajala H, Ikram A, Rizzo F, Qureshi A, Begunova L, Matsoukas S, Vigilante N, Salazar-Marioni S, Abdalkader M, Gordon W, Soomro J, Turabova C, Vivanco-Suarez J, Mokin M, Yavagal D, Jovin T, Sheth S, Ortega-Gutierrez S. Safety Outcomes of Mechanical Thrombectomy Versus Combined Thrombectomy and Intravenous Thrombolysis in Tandem Lesions. Stroke 2023, 54: 2522-2533. PMID: 37602387, PMCID: PMC10599264, DOI: 10.1161/strokeaha.123.042966.Peer-Reviewed Original ResearchMeSH KeywordsBrain IschemiaCerebral InfarctionFibrinolytic AgentsHematomaHumansIntracranial HemorrhagesMechanical ThrombolysisPlatelet Aggregation InhibitorsStrokeThrombectomyThrombolytic TherapyTreatment OutcomeConceptsRisk of sICHParenchymal hematoma type 2Symptomatic intracranial hemorrhageRankin Scale score 0Intravenous antiplatelet therapyIntravenous thrombolysisFavorable functional outcomeMechanical thrombectomyHemorrhagic transformationFunctional outcomeType 2Antiplatelet therapyHospital mortalitySuccessful reperfusionComplete reperfusionScore 0Tandem lesionsAnterior circulation tandem lesionsExcellent functional outcomeIVT treatmentStroke centersMulticenter cohortPrimary outcomeRevascularization techniquesAlone group